Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Particle Imaging and Analysis System

February 11, 2011 7:36 am | Product Releases | Comments

The FlowCAM Front-Fill Illumination particle imaging and analysis system from Fluid Imaging Technologies is the first to feature bidirectional front and back lighting, which illuminates the surfaces of opaque particles and reveals their true colors and textures.


SEC-LS Detector

February 11, 2011 7:33 am | Product Releases | Comments

Malvern Instruments has launched the Zetasizer µV with OmniFACE and OmniSEC, a SEC-LS (size exclusion chromatography - light scattering) detector package dedicated to protein analysis.


Vanda Profits Up $11.4M Over Previous Year

February 11, 2011 7:23 am | News | Comments

Vanda Pharmaceuticals Inc. said it turned a profit in the fourth quarter on reduced expenses, including lower costs related to its schizophrenia drug Fanapt.


Momenta Earns $36.3M in 4th

February 11, 2011 7:12 am | News | Comments

Momenta Pharmaceuticals Inc. said it turned a fourth-quarter profit and achieved profitability for the first time in 2010 as a generic version of the anti-clotting drug Lovenox pushed revenue growth.


Preladenant Reduces Down Time in Parkinson's Patients

February 11, 2011 7:07 am | News | Comments

Preladenant, a non-dopaminergic medication, reduces off time in patients with Parkinson's disease receiving standard dopamine therapy. The findings suggest that preladenant may offer a new supplemental treatment with fewer complications.


Discovery May Lead to Alzheimer's Treatments

February 11, 2011 7:01 am | News | Comments

Scientists have made a discovery that has the potential for use in the early diagnosis and eventual treatment of plaque-related diseases such as Alzheimer's disease and Type 2 diabetes.


TB-402 Performs Well in VTE Trial

February 11, 2011 6:51 am | News | Comments

BioInvent International AB and co-development partner ThromboGenics NV have announced positive results of a TB-402 Phase 2 trial, evaluating the product’s efficacy and safety for the prevention of venous thromboembolism after orthopaedic surgery.


Juvista Fails Late-Stage Trial

February 11, 2011 6:46 am | News | Comments

Renovo Group plc, which develops drugs to reduce scarring, improve wound healing, and enhance tissue regeneration, announces that its first EU Phase 3 trial for Juvista in scar revision surgery (REVISE) did not meet its primary or secondary endpoints.


Shire Profits Drop On Costs

February 11, 2011 6:42 am | News | Comments

Irish drug developer Shire Plc. said its fourth-quarter profit fell on higher costs, but the results met Wall Street expectations. The company earned $165.1 million, down from $174.3 million.


Lilly Names New Cancer President

February 11, 2011 6:39 am | News | Comments

Eli Lilly and Co. named company insider Sue Mahony as president of its cancer drug business. The change is effective immediately. Mahony has worked at Eli Lilly for about 10 years, the company said.


Principal Investigator System Enables CROs to Improve Bioanalytical Study Management

February 10, 2011 10:26 am | by Richard LeLacheur, Vice President, PharmaNet, Princeton, NJ | Articles | Comments

In order to ensure smooth operation during bioanalytical studies, a novel model, where a principal investigator with direct control over the entire study is the core of the project, has been developed.


Micro Bioreactor System

February 10, 2011 6:08 am | Product Releases | Comments

The Automation Partnership, a leader in the design and development of innovative automation for life science applications, has announced its micro bioreactor system, ambr, is now available with integrated Beckman Coulter Vi-CELL Cell Viability Analyser.


Infrared Spectrometer

February 10, 2011 6:02 am | Product Releases | Comments

PerkinElmer Inc. announced the launch of the Frontier Infrared Spectrometer, a high performance infrared (FT-IR) spectrometer built using PerkinElmer’s industry-leading spectroscopy expertise.


Fluidigm Announces IPO Pricing

February 10, 2011 5:42 am | News | Comments

Fluidigm Corporation announced the pricing of its initial public offering of 5,558,333 shares of its common stock at a price to the public of $13.50 per share. The shares of common stock have been approved to trade on The NASDAQ Global Market under the symbol "FLDM."


Auxilium Revenue Up, Profit Down

February 10, 2011 5:38 am | News | Comments

Auxilium Pharmaceuticals Inc. said its fourth-quarter loss widened, even though revenue grew 29 percent, as the biopharmaceutical company incurred growing expenses tied to its Dupuytren's contracture treatment Xiaflex.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.